Anika Therapeutics (ANIK) Other Accumulated Expenses (2011 - 2026)
Anika Therapeutics (ANIK) posted quarterly Other Accumulated Expenses of $326000.0 for Q2 2026, down 49.14% year-over-year from $641000.0 in Q2 2025, and down 31.94% quarter-over-quarter from $479000.0 in Q1 2026.
Anika Therapeutics (ANIK) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Other Accumulated Expenses for 15 consecutive years, with $326000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Accumulated Expenses fell 49.14% year-over-year to $326000.0; the TTM figure through Jun 2026 stood at $326000.0 (down 49.14% YoY), while the FY2025 annual figure was $468000.0, down 38.82% from the prior year.
- Other Accumulated Expenses slipped to $326000.0 in Q2 2026 per ANIK's latest filing, from $479000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.1 million in Q1 2022 and bottomed at $326000.0 in Q2 2026.
- Historically, Other Accumulated Expenses has averaged $596055.6 across 5 years, with a median of $515000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses plunged 97.14% — and 2024, when it surged 126.33%.
- Anika Therapeutics' Other Accumulated Expenses stood at $510000.0 in 2022, then tumbled by 33.73% to $338000.0 in 2023, then surged by 126.33% to $765000.0 in 2024, then sank by 38.82% to $468000.0 in 2025, then tumbled by 30.34% to $326000.0 in 2026.
- Business Quant data shows ANIK's Other Accumulated Expenses at $326000.0 in Q2 2026, $479000.0 in Q1 2026, and $468000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 326,000.00 |
| Mar 31, 2026 | 479,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | 750,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Mar 31, 2025 | 776,000.00 |
| Dec 31, 2024 | 765,000.00 |
| Sep 30, 2024 | 378,000.00 |
| Jun 30, 2024 | 517,000.00 |
| Mar 31, 2024 | 477,000.00 |
| Dec 31, 2023 | 338,000.00 |
| Sep 30, 2023 | 513,000.00 |
| Jun 30, 2023 | 542,000.00 |
| Mar 31, 2023 | 575,000.00 |
| Dec 31, 2022 | 510,000.00 |
| Sep 30, 2022 | 496,000.00 |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.06 Mn |
| Sep 30, 2021 | 17.34 Mn |